Home - DeckTherapeutics

Pioneering neuroprotection using acute omega-3 fatty acid therapeutics

Brain cell death following hypoxia-ischemia is inhibited by the pleiotropic effects of bioactive omega-3 fatty acids

THDG3 is a novel semi-synthetic omega-3 fatty acid glyceride emulsion

Intravenous THDG3 is a potent neuroprotectant and far superior to any tested omega-3 triglyceride emulsion

The rare neonatal condition HIE is the lead indication for THDG3

Neonatal hypoxic-ischemic encephalopathy (HIE) is the medical term for brain damage in newborns who have received too little oxygen during labor and/or delivery

THDG3

THDG3:

A neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries THDG3 was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline

THDG3

THDG3:

A neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries THDG3 was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline

Indications

Neonatal hypoxic-ischemic encephalopathy (HIE)

Insufficient supply of oxygen during labor and/or delivery causes brain injury in tens of thousands of newborns every year. HIE is the most common cause of cerebral palsy in full-term infants

Indications

Ischemic stroke is the 5^th most common cause of death in the US

Ischemic stroke is one of the largest and most costly unmet medical needs. Tissue plasminogen activator (t-PA) and thrombectomy can be used to restore blood flow in some patients but no neuroprotectant is approved to date